First Reported Nonpeptide AT1 Receptor Agonist (L-162,313) Acts as an AT2 Receptor Agonist in Vivo

Journal of Medicinal Chemistry

Volumn 47, Issue 6, 2004, Pages 1536-1546

  Wan, Yiqian ^a   Wallinder, Charlotta ^a   Johansson, Berndt ^b   Holm, Mathias ^b   Mahalingam, A K ^a   Wu, Xiongyu ^a   Botros, Milad ^b   Karlén, Anders ^a   Pettersson, Anders ^b   Nyberg, Fred ^a   Fändriks, Lars ^b   Hallberg, Anders ^a   Alterman, Mathias ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; L 162313; LOSARTAN; UNCLASSIFIED DRUG; ANGIOTENSIN RECEPTOR ANTAGONIST; BIPHENYL DERIVATIVE; IMIDAZOLE DERIVATIVE; PYRIDINE DERIVATIVE;

ALDOSTERONE RELEASE; ALKYLATION; ARTICLE; BINDING AFFINITY; CARBON NUCLEAR MAGNETIC RESONANCE; DRUG EFFECT; DRUG ISOLATION; DUODENUM MUCOSA; LIGAND BINDING; PROTON NUCLEAR MAGNETIC RESONANCE; RECEPTOR BINDING; RECEPTOR BLOCKING; VASOCONSTRICTION; ANIMAL; BINDING COMPETITION; DRUG ANTAGONISM; DRUG POTENTIATION; DUODENUM; FEMALE; IN VITRO STUDY; INTESTINE MUCOSA; MALE; METABOLISM; MYOMETRIUM; RADIOASSAY; RAT; SECRETION; SPRAGUE DAWLEY RAT; SWINE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; BINDING, COMPETITIVE; BIPHENYL COMPOUNDS; DUODENUM; FEMALE; IMIDAZOLES; INTESTINAL MUCOSA; MALE; MYOMETRIUM; PYRIDINES; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ANGIOTENSIN, TYPE 1; RECEPTOR, ANGIOTENSIN, TYPE 2; SWINE;

EID: 1542268165     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm031031i     Document Type: Article

References (34)

1. (a) De Gasparo, M.; Catt, K. J.; Inagami, T.; Wright, J. W.; Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 2000, 52, 415-472.
2. (b) Birkenhager, W. H.; de Leeuw, P. W. Non-peptide angiotensin type 1 receptor antagonists in the treatment of hypertension. J. Hypertens. 1999, 17, 873-881.
3. (c) Greenlee, W. J. Hypertension - Treatment by blockade of the renin-angiotensin system. Pharmacochem. Lib. 1997, 28, 97-107.
4. (d) Timmermans, P. B. M. W. M.; Smith, R. D. Antihypertensive Agents. Burger's Medicinal Chemistry and Drug Discovery, 5th ed.; John Wiley & Sons: New York, 1996.
5. (e) Wexler, R. R.; Greenlee, W. J.; Irvin, J. D.; Goldberg, M. R.; Prendergast, K.; Smith, R. D.; Timmermans, P. B. M. W. M. Nonpeptide angiotensin II receptor antagonists: The next generation in antihypertensive therapy. J. Med. Chem. 1996, 39, 625-656.
6. (f) Ashton, W. T.; Chang, L. L.; Flanagan, K. L.; Mantlo, N. B.; Ondeyka, D. L.; Kim, D.; de Laszlo, S. E.; Glinka, T. W.; Rivero, R. A.; Kevin, N. J.; Chang, R. S. L.; Siegl, P. K. S.; Kivlighn, S. D.; Greenlee, W. J. AT1/AT2-balanced angiotensin II antagonists. Euro. J. Med. Chem. 1995, 30, 255-266.
7. (g) Ashton, W. T. Nonpeptide angiotensin II receptor antagonists. Exp. Opin. Invest. Drugs 1994, 3, 1105-1142.
8. (h) Duncia, J. V.; Carini, D. J.; Chiu, A. T.; Johnson, A. L.; Price, W. A.; Wong, P. C.; Wexler, R. R.; Timmermans, P. B. M. W. M. The discovery of DuP 753, a potent, orally active nonpeptide angiotensin II receptor antagonist. Med. Res. Rev. 1992, 12, 149-191.
9. (a) Perlman, S.; Schambye, H. T.; Rivero, R. A.; Greenlee, W. J.; Hjorth, S. A.; Schwartz, T. W. Non-peptide angiotensin agonist. Functional and molecular interaction with the AT1 receptor. J. Biol. Chem. 1995, 270, 1493-1496.
10. (b) Kivlighn, S. D.; Huckle, W. R.; Zingaro, G. J.; Rivero, R. A.; Lotti, V. J.; Chang, R. S. L.; Schorn, T. W.; Kevin, N.; Johnson, R. G., Jr.; Greenlee, W. J.; Siegl, P. K. S. Discovery of L-162,313: a nonpeptide that mimics the biological actions of angiotensin II. Am. J. Physiol. 1995, 268, R820-R823.
11. Perlman, S.; Costa-Neto, C. M.; Miyakawa, A. A.; Schambye, H. T.; Hjorth, S. A.; Paiva, A. C. M.; Rivero, R. A.; Greenlee, W. J.; Schwartz, T. W. Dual agonistic and antagonistic property of nonpeptide angiotensin AT1 ligands: susceptibility to receptor mutations. Mol. Pharmacol. 1997, 51, 301-311.
12. Huckle, W. R.; Kivlighn, S. D.; Zingaro, G. J.; Kevin, N. J.; Rivero, R. A.; Chang, R. S. L.; Greenlee, W. J.; Siegl, P. K. S.; Johnson, R. G. Angiotensin II receptor-mediated activation of phosphoinositide hydrolysis and elevation of mean arterial pressure by a nonpeptide, L-163, 491. Can. J. Physiol. Pharmacol. 1994, 72, 543.
13. Gallinat, S.; Busche, S.; Raizada, M. K.; Sumners, C. The angiotensin II type 2 receptor: an enigma with multiple variations. Am. J. Physiol. 2000, 278, E357-E374.
14. de Gasparo, M.; Siragy, H. M. The AT2 receptor: fact, fancy and fantasy. Regul. Peptides 1999, 81, 11-24.
15. Johansson, B.; Holm, M.; Ewert, S.; Casselbrant, A.; Pettersson, A.; Fandriks, L. Angiotensin II type 2 receptor-mediated duodenal mucosal alkaline secretion in the rat. Am. J. Physiol. 2001, 280, G1254-G1260.
16. Blankley, C. J.; Hodges, J. C.; Klutchko, S. R.; Himmelsbach, R. J.; Chucholowski, A.; Connolly, C. J.; Neergaard, S. J.; Van Nieuwenhze, M. S.; Sebastian, A.; Quin, J., III. Synthesis and structure-activity relationships of a novel series of nonpeptide angiotensin II receptor binding inhibitors specific for the AT2 subtype. J. Med. Chem. 1991, 34, 3248-3260.
17. Carini, D. J.; Duncia, J. V.; Aldrich, P. E.; Chiu, A. T.; Johnson, A. L.; Pierce, M. E.; Price, W. A.; Santella, J. B., 3rd; Wells, G. J.; Wexler, R. R.; Wong, P. C.; Yoo, W.-E.; Timmermans, P. B. M. W. M. Nonpeptide angiotensin II receptor antagonists: the discovery of a series of N-(biphenylylmethyl)imidazoles as potent, orally active antihypertensives. J. Med. Chem. 1991, 34, 2525-2547.
18. (a) de Laszlo, S. E.; Quagliato, C. S.; Greenlee, W. J.; Patchett, A. A. ; Chang, R. S. L.; Lotti, V. J.; Chen, T. B.; Scheck, S. A.; Faust, K. A.; Kivlighn, S. D.; Schorn, T. S.; Zingaro, G. J.; Siegl, P. K. S. A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor. J. Med. Chem. 1993, 36, 3207-3210.
19. (b) Glinka, T. W.; de Laszlo, S. E.; Tran, J.; Chang, R. S.; Chen, T. B. ; Lotti, V. J.; Greenlee, W. J. L-161,-638: a potent AT2 selective quinazolinone angiotensin II binding inhibitor. Bioorg. Med. Chem. Lett. 1994, 4, 1479-1484.
20. (c) Glinka, T. W.; de Laszlo, S. E.; Siegl, P. K. S.; Chang, R. S.; Kivlighn, S. D.; Schorn, T. S.; Faust, K. A.; Chen, T. B.; Zingaro, G. J.; et al. A new class of balanced AT1/AT2 angiotensin II antagonists: quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalities. Bioorg. Med. Chem. Lett. 1994, 4, 81-86.
21. (d) Chakravarty, P. K.; Strelitz, R. A.; Chen, T. B.; Chang, R. S. L.; Lotti, V. J.; Zingaro, G. J.; Schorn, T. W.; Kivlighn, S. D.; Siegl, P. K. S.; Patchett, A. A.; Greenlee, W. J. Quinazolinone biphenyl acylsulfonamides: a potent new class of angiotensin-II receptor antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 75-80.
22. (e) de Laszlo, S. E.; Chang, R. S.; Chen, T.-B.; Faust, K. A.; Greenlee, W. J.; Kivlighn, S. D.; Lotti, V. J.; O'Malley, S. S.; Schorn, T. W.; et al. The SAR of 6-(N-alkyl-N-acyl)-2-propyl-3-[(2′ -(tetrazol-5-yl)biphen-4-yl)methyl] quinazolinones as balanced affinity antagonists of the human AT1 and AT2 receptors. Bioorg. Med. Chem. Lett. 1995, 5, 1359-1364.
23. (f) de Laszlo, S. E.; Glinka, T. W.; Greenlee, W. J.; Ball, R.; Nachbar, R. B.; Prendergast, K. The design, binding affinity prediction and synthesis of macrocyclic angiotensin II AT1 and AT2 receptor antagonists. Bioorg. Med. Chem. Lett. 1996, 6, 923-928.
24. (g) Levin, J. I.; Chan, P. S.; Porter, R. S. 2,3,6-Substituted quinazolinones as angiotensin II receptor antagonists. Drugs Future 1995, 20, 55-65.
25. (a) Kevin, N. J.; Rivero, R. A.; Greenlee, W. J.; Chang, R. S. L.; Chen, T. B. Substituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II AT1 and AT2 receptors. Bioorg. Med. Chem. Lett. 1994, 4, 189-194.
26. (b) Kivlighn, S.; Lotti, V. J.; Rivero, R. A.; Siegl, P. K. S.; Zingaro, G. J. Preparation of thiophene-substituted imidazo[4,5-b]pyridine angiotensin II receptor agonists. British UK Pat. Appl. GB 2281298 (Merck and Co., Inc., Rahway, NJ) 1995.
27. Senanayake, C. H.; Fredenburgh, L. E.; Reamer, R. A.; Liu, J.; Roberts, F. E.; Humphrey, G.; Thompson, A. A.; Larsen, R. D.; Verhoeven, T. R.; Reider, P. J.; Sinkai, I. New approach to the imidazolutidine moiety of MK-996. Heterocycles 1996, 42, 821-830.
28. (a) Dudley, D. T.; Panek, R. L.; Major, T. C.; Lu, G. H.; Bruns, R. F.; Klinkefus, B. A.; Hodges, J. C.; Weishaar, R. E. Subclasses of angiotensin II binding sites and their functional significance. Mol. Pharmacol. 1990, 38, 370-377.
29. (b) Nielsen, A. H.; Schauser, K.; Winther, H.; Dantzer, V.; Poulsen, K. Angiotensin II receptors and renin in the porcine uterus: myometrial AT2 and endometrial AT1 receptors are down-regulated during gestation. Clin. Exp. Pharmacol. Physiol. 1997, 24, 309-314.
30. 3(-) transport by mammalian duodenum in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 1982, 243, G348-358.
31. Mantlo, N. B.; Kim, D.; Ondeyka, D. L.; Chang, R. S. L.; Kivlighn, S. D. ; Sieg, P. K. S.; Greenlee, W. J. Imidazo[4,5-b]pyridine-based AT1/AT2 angiotensin II receptor antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 17-22.
32. Johansson, B.; Holm, M.; Chen, L. H.; Pettersson, A.; Jonson, C.; Fandriks, L. ANG II prolongs splanchnic nerve-mediated inhibition of duodenal mucosal alkaline secretion in the rat. Am. J. Physiol.-Regul. Integr. Comput. Physiol. 1997, 273, R942-R946.
33. Dudley, D. T.; Panek, R. L.; Major, T. C.; Lu, G. H.; Bruns, R. F.; Klinkefus, B. A.; Hodges, J. C.; Weishaar, R. E. Subclasses of angiotensin-II binding-sites and their functional-significance. Mol. Pharmacol. 1990, 38, 370-377.
34. Nielsen, A. H.; Schauser, K.; Winther, H.; Dantzer, V.; Poulsen, K. Angiotensin II receptors and renin in the porcine uterus: Myometrial AT(2) and endometrial AT(1) receptors are down-regulated during gestation. Clin. Exp. Pharmacol. Physiol. 1997, 24, 309-314.